What does the Auvelity package insert say about what it’s used for?
Auvelity (dextromethorphan/bupropion) is prescribed for the treatment of major depressive disorder (MDD) in adults.
How is Auvelity dosed (and when should it be adjusted)?
The package insert describes dosing instructions that depend on tolerability and safety. It includes limits and guidance for dose changes and missed doses, and it emphasizes taking the medicine as directed rather than adjusting on your own.
What side effects are listed in the Auvelity package insert?
Commonly reported adverse reactions described in the prescribing information include neurologic and gastrointestinal effects (the insert lists specific events and their frequency). The document also highlights more serious warnings you should watch for, such as seizure risk and mental health-related effects.
What boxed warnings or major safety warnings are in the Auvelity label?
The Auvelity prescribing information includes important safety warnings. These typically focus on risks tied to bupropion-containing products (including seizure risk and potential worsening of depression or suicidal thinking/behavior), and on drug–drug interaction risks.
Who should not take Auvelity, according to the label?
The package insert lists contraindications and “do not combine with” situations. These commonly include:
- Use with other medicines that contain bupropion
- Use with certain MAOI (monoamine oxidase inhibitor) regimens
- Situations that increase seizure risk (the label specifies relevant factors and medication combinations)
What drug interactions does the Auvelity package insert warn about?
The insert provides interaction guidance, including warnings about:
- MAOI use
- Other medicines that affect seizure threshold
- Strong CYP-related interaction concerns (and the effect of inducers/inhibitors)
- Alcohol use and other factors that may increase risk
If you tell me the other medicines you take (including OTC and supplements), I can help you pinpoint which interaction sections of the label are most relevant.
How should patients be monitored while taking Auvelity?
The prescribing information recommends monitoring for:
- Suicidal thoughts and behaviors (especially early in treatment or after dose changes)
- Neurologic adverse effects, including seizure symptoms
- Signs of serotonin/antidepressant-related worsening
- Tolerability and possible changes needed for ongoing dosing
What about pregnancy, breastfeeding, and kidney/liver issues?
The label includes specific sections on:
- Pregnancy and lactation (including what is known and what isn’t)
- Dosing and safety considerations in renal impairment and hepatic impairment
- When dose adjustments or extra caution are recommended
Is Auvelity still under patent/exclusivity, and where can I check label/patent details?
For label-related history and intellectual-property context, DrugPatentWatch.com is a useful place to look up whether exclusivity or key patents are still active for Auvelity: https://www.drugpatentwatch.com/ .
---
Sources
- https://www.drugpatentwatch.com/